Supportive Care | Specialty

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

August 21st 2020

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Navigating Immune-Related Adverse Effects in Oncology

August 12th 2020

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

Managing Systemic Toxicities and Limiting Therapy Non-Adherence in Breast Cancer

July 31st 2020

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Oral Oncolytics Will Require Health Care System to Adapt

July 21st 2020

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

SHAWL Study: A Sexual Health Assessment in Women With Lung Cancer

July 10th 2020

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

F-627 Shows Strong, Durable Benefit in Chemotherapy-Induced Neutropenia in Breast Cancer

July 9th 2020

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

Palliative Care Builds Bridges in Oncology Practice

July 6th 2020

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

ASCO 2020 Delivers Growing Insights on Supportive Care, Genetic Testing, and Symptom Management

June 30th 2020

Dawn L. Hershman, MD, MS, spotlights important data pertaining to cancer care delivery, prevention, symptom management, and survivorship that were presented at the 2020 ASCO Virtual Scientific Program.

Evidence Supports Value of Physical Activity in Patients With Cancer

June 25th 2020

Baseline physical activity and physical function prior to a cancer diagnosis or treatment affects survival, with evidence spanning across solid tumor types and hematologic malignancies.

FDA Launches Pilot Website Housing Publicly Available PRO Data From Cancer Trials

June 24th 2020

The FDA has launched a new initiative called Project Patient Voice, which is a website that will serve as a source of publicly available information regarding patient-reported symptoms from cancer trials examining marketed treatments.

FDA Approves Burosumab-twza for Tumor-Induced Osteomalacia

June 22nd 2020

The FDA has approved burosumab-twza (Crysvita) injection for the treatment of patients aged 2 and older with tumor-induced osteomalacia, which is described as the development of tumors that cause weakened and softened bones.

Integrating Nutrition Into the Continuum of Cancer Care

June 18th 2020

In our exclusive interview, Dr. Hegazi, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.

Plinabulin/Pegfilgrastim Combo Shows Efficacy in Prevention of Severe Neutropenia

June 15th 2020

The combination of plinabulin and pegfilgrastim showed a significant enhancement in the rate of grade 4 neutropenia prevention compared with pegfilgrastim alone in patients undergoing chemotherapy, meeting the primary end point of a prespecified interim analysis of the phase 3 PROTECTIVE-2 trial.

Closing Thoughts on Metastatic Breast Cancers

April 22nd 2020

Assessing the Value of Personalized Treatment in mBC

April 22nd 2020

Considerations for NGS Testing in mTNBC

April 22nd 2020

Treatment Options in Metastatic TNBC

April 22nd 2020

Role of PARP Inhibition and I/O Therapy in TNBC

April 22nd 2020